CA-XSOLLA/GDC
21.3.2022 12:02:11 CET | Business Wire | Press release
Xsolla , a global video game commerce company, is attending and presenting at GDC (Game Developers Conference) , the biggest game conference in the world, today through March 25th in San Francisco, California, USA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005435/en/
Xsolla is hosting six informative speaking sessions on Tuesday, March 22nd, including a keynote from President Chris Hewish. Additionally, Xsolla is exhibiting at Moscone South S657, starting on Wednesday, March 23rd, where attendees can meet with Xsolla experts and get a preview of the latest products and solutions designed to accelerate video game commerce in 2022.
“I’m excited to return to GDC in person and to kick off Xsolla’s series of trending topic speaker sessions,” Hewish said. “It’s great to see old friends and meet new people from all over the world who share our passion for video games.”
The Xsolla team is sharing industry updates and their expertise on the tools and services available for video game developers and publishers. Topics will range from mobile game monetization outside of the app store, payments for the enterprise , and token-based systems for digital content with a new NFT Checkout to emerging market opportunities and prelaunch funding . Video-on-demand of the sessions will be available later in the week for those who could not attend to watch and learn.
Tuesday, March 22 | 9:30am - 10:30am [Add to iCal
]
GOING GLOBAL, STAYING LOCAL: HELPING GAME DEVELOPERS SUCCEED
Great games don’t just appear. They start as ideas, and only through the curiosity, dedication, and grit of people all over the globe do they come to life. Xsolla President Chris Hewish outlines ways to ensure that every developer has the same opportunity to see their game become a part of how we play.
Tuesday, March 22 | 10:50am - 11:50am [Add to iCal
]
INSIDE THE WALLED PAYMENT GARDEN: A GUIDE TO MOBILE MARKET FREEDOM
In this session, Anthony Mendoza and Miikka Luotio share a frank discussion on how developers can break into mobile gaming's 'walled payment garden' and grow their games just as many others have already done.
Tuesday, March 22 | 1:20pm - 1:50pm [Add to iCal
]
GAME OF FUNDS: SUCCESS IS COMING
Xsolla’s dynamic duo of funding, Justin Berenbaum and Lily Goldner, host special guests David Martinez from Raw Fury and Ken Seto from Massive Damage Games in a fireside chat, where you’ll discover how to improve your chances and create business alliances.
Tuesday, March 22 | 2:10pm - 2:40pm [Add to iCal
]
BEYOND CREDIT: TAKING ADVANTAGE OF EMERGING PAYMENT METHODS
WORLDWIDE
"Cash, check or charge?" It used to be that these were the only options when handling payments. Now there are hundreds. Berkley Egenes leads a team of Xsolla regional experts as they discuss how to control the chaos and take advantage of emerging payment methods around the globe.
Tuesday, March 22 | 3:00pm - 3:30pm [Add to iCal
]
"THINGS I WISH I KNEW SOONER" ABOUT THE GAME INDUSTRY
Xsolla's Sam Gaglani hosts a panel of games industry pros, including Kara Bilkiss from Rogue Games, Michael Lewis from Take-Two Interactive, and Andreea Enache from Secret Society Games who've "been there, done that" as they share their wisdom and insights. They will focus on topics that affect developers at any studio and discuss things they wish they had known sooner about working in the industry.
Tuesday, March 22 | 3:50pm - 4:20pm [Add to iCal
]
HYBRID TIMES: GAME DEVELOPERS SOUND OFF ON WORKING FROM HOME, COMPENSATION, AND CAREER
The industry-leading platform 80 Level asked the gaming community about recent challenges and opportunities, and over 800 game developers shared their experiences. Kirill Tokarev, Editor in Chief at 80 Level, highlights what these responses reveal about our past and what the future has in store.
Book a meeting with Xsolla’s global game commerce experts to discover how they can help expand your video game commerce in the changing games industry.
For more information on how to attend speaking sessions and connect with Xsolla at GDC 2022, visit https://xsolla.com/gdc2022
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world to support major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more. For additional information and to learn more, please visit xsolla.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom